Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

Importance The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. Objective To determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX. Design, Setting, and Participants The evaluated biomarkers for MMR status were determined from prospectively collected tumor blocks from patients treated with FOLFOX in 2 open-label, phase 3 randomized clinical trials: NCCTG N0147 and PETACC8. The studies were conducted in general community practices, private practices, and institutional practices in the United States and Europe. All participants had stage III colon adenocarcinoma. They were enrolled in NCCTG N0147 from February 2004 to November 2009 and in PETACC8 from December 2005 to November 2009. Interventions Patients in the clinical trials were randomly assigned to receive 6 months of chemotherapy with FOLFOX or FOLFOX plus cetuximab. Only those patients treated with FOLFOX alone were included in the present study. Main Outcomes and Measures Association of MMR status with DFS was analyzed using a stratified Cox proportional hazards model. Multivariable models were adjusted for age, sex, tumor grade, pT/pN stage, tumor location, ECOG (Eastern Cooperative Oncology Group) performance status, and BRAF V600E mutational status. Results Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501. Of these, 252 (10.1%) showed deficient MMR status (dMMR; 134 women, 118 men; median age, 59 years), while 2249 (89.9%) showed proficient MMR status (pMMR; 1020 women, 1229 men; median age, 59 years). The 3-year DFS rates in the dMMR and pMMR groups were 75.6% and 74.4%, respectively. By multivariate analysis, patients with dMMR phenotype had significantly longer DFS than those with pMMR (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.97; P = .03). Conclusions and Relevance The deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. Trial Registration clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.

[1]  J. Taïeb,et al.  Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. , 2016, Journal of the National Cancer Institute.

[2]  P. Laurent-Puig,et al.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. , 2016, JAMA oncology.

[3]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Sinicrope,et al.  Implications of mismatch repair-deficient status on management of early stage colorectal cancer. , 2015, Journal of gastrointestinal oncology.

[5]  L. Collette,et al.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[6]  F. Sinicrope,et al.  Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAFV600E Mutations in Patients with Lymph-Node-Positive Colon Cancer , 2014, Current Colorectal Cancer Reports.

[7]  D. Sargent,et al.  Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Greg Yothers,et al.  Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value , 2012, Clinical Cancer Research.

[9]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[10]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Validire,et al.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Monica Chiogna,et al.  A modified LOESS normalization applied to microRNA arrays: a comparative evaluation , 2009, Bioinform..

[14]  B. Efron Empirical Bayes Estimates for Large-Scale Prediction Problems , 2009, Journal of the American Statistical Association.

[15]  J. Lau,et al.  MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. , 2009, Pharmacogenomics.

[16]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Wan,et al.  The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers , 2009, Autophagy.

[18]  Olga Vitek,et al.  Statistical design of quantitative mass spectrometry-based proteomic experiments. , 2009, Journal of proteome research.

[19]  Sylvain Pradervand,et al.  Impact of normalization on miRNA microarray expression profiling. , 2009, RNA.

[20]  J. Meyerhardt,et al.  Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Gentleman,et al.  Quality Assessment and Data Analysis for microRNA Expression Arrays , 2008, Nucleic acids research.

[22]  J. Benítez,et al.  Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. , 2009, Gynecologic oncology.

[23]  F. Sinicrope,et al.  Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 , 2008, Clinical Cancer Research.

[24]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[25]  W. Grady,et al.  Genomic and epigenetic instability in colorectal cancer pathogenesis. , 2008, Gastroenterology.

[26]  D. Notterman,et al.  CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer , 2008, Clinical Cancer Research.

[27]  D. Sargent,et al.  Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas , 2008, Clinical Cancer Research.

[28]  J. Meyerhardt,et al.  Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Yi-xue Li,et al.  Comparison of normalization methods with microRNA microarray. , 2008, Genomics.

[30]  A. Kwong,et al.  Localization of hRad9 in breast cancer , 2008, BMC Cancer.

[31]  G. Kroemer,et al.  Bcl-2 family members: Dual regulators of apoptosis and autophagy , 2008, Autophagy.

[32]  D. Sargent,et al.  Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers , 2008, Clinical Cancer Research.

[33]  T. Therneau,et al.  A statistical model for iTRAQ data analysis. , 2008, Journal of proteome research.

[34]  Göran Roos,et al.  Breast cancer survival is associated with telomere length in peripheral blood cells. , 2008, Cancer research.

[35]  Walter Park,et al.  Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. , 2008, JAMA.

[36]  M. Cummings,et al.  The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. , 2008, Human pathology.

[37]  Terry M Therneau,et al.  Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. , 2008, Journal of proteome research.

[38]  E. Salido,et al.  Expression of DNA Damage Checkpoint Protein Hus1 in Epithelial Ovarian Tumors Correlates With Prognostic Markers , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[39]  J. Califano,et al.  Downregulation of RAD17 in head and neck cancer , 2008, Head & neck.

[40]  Jason C Hsu,et al.  A Comparison of Normalization Techniques for MicroRNA Microarray Data , 2008, Statistical applications in genetics and molecular biology.

[41]  A. Letai,et al.  Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. , 2007, Cancer research.

[42]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[43]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[44]  I. Sobhani,et al.  High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas , 2007, Gut.

[45]  T. Wurdinger,et al.  Molecular therapy in the microRNA era , 2007, The Pharmacogenomics Journal.

[46]  W. Pao,et al.  Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.

[47]  A. Strasser,et al.  Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics , 2007, PLoS medicine.

[48]  S. Hankinson,et al.  Body shape throughout life and correlations with IGFs and GH. , 2007, Endocrine-related cancer.

[49]  N. Vilarrasa,et al.  Low 25-hydroxyvitamin D concentrations in obese women: Their clinical significance and relationship with anthropometric and body composition variables , 2007, Journal of endocrinological investigation.

[50]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[51]  Jason H. Moore,et al.  Evaporative cooling feature selection for genotypic data involving interactions , 2007, Bioinform..

[52]  W. Willett,et al.  A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. , 2007, Journal of the National Cancer Institute.

[53]  Liat Mizrachy,et al.  Differential Interactions Between Beclin 1 and Bcl-2 Family Members , 2007, Autophagy.

[54]  Jeffery T. Sloan,et al.  Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Nektarios Tavernarakis,et al.  Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 , 2007, The EMBO journal.

[56]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[57]  Yigong Shi,et al.  Crystal Structure of the Bcl-XL-Beclin 1 Peptide Complex , 2007, Journal of Biological Chemistry.

[58]  D. Sargent,et al.  Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability , 2007, International journal of cancer.

[59]  Norman Wolmark,et al.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Stallings,et al.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. , 2007, Cancer research.

[61]  C. Croce,et al.  CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control , 2006, Proceedings of the National Academy of Sciences.

[62]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.

[63]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[64]  A. Strasser,et al.  Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction , 2006, The Journal of experimental medicine.

[65]  Gábor Bartha,et al.  Activation of an oncogenic microRNA cistron by provirus integration , 2006, Proceedings of the National Academy of Sciences.

[66]  D. Sargent,et al.  Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers , 2006, The American Journal of Gastroenterology.

[67]  N. Wolmark,et al.  Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. , 2006, Journal of the National Cancer Institute.

[68]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[69]  P. Codogno,et al.  Atg5: more than an autophagy factor , 2006, Nature Cell Biology.

[70]  Terry M. Therneau,et al.  Joint estimation of calibration and expression for high-density oligonucleotide arrays , 2006, Bioinform..

[71]  E. Furth,et al.  Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster , 2006, Nature Genetics.

[72]  D. Sargent,et al.  Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. , 2006, Gastroenterology.

[73]  Jason H. Moore,et al.  Feature Selection using a Random Forests Classifier for the Integrated Analysis of Multiple Data Types , 2006, 2006 IEEE Symposium on Computational Intelligence and Bioinformatics and Computational Biology.

[74]  G. Zachos,et al.  Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil , 2006, Oncogene.

[75]  Haiying Zhang,et al.  Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase–activated protein kinase 2 in mediating DNA damage–induced cell cycle arrest: implications for cancer therapy , 2006, Molecular Cancer Therapeutics.

[76]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[77]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[78]  F. Sinicrope Targeting cyclooxygenase‐2 for prevention and therapy of colorectal cancer , 2006, Molecular carcinogenesis.

[79]  D. Sargent,et al.  Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability , 2006, Clinical Cancer Research.

[80]  T. Rohan,et al.  Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[81]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[82]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Y. Okita,et al.  His239Arg SNP of HRAD9 is associated with lung adenocarcinoma , 2006, Cancer.

[84]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[85]  yang-xin fu,et al.  Tumor-infiltrating T lymphocytes: friends or foes? , 2006, Laboratory Investigation.

[86]  Leonid Kruglyak,et al.  Telomere Length as a Quantitative Trait: Genome-Wide Survey and Genetic Mapping of Telomere Length-Control Genes in Yeast , 2006, PLoS genetics.

[87]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Alan R. Dabney ClaNC: point-and-click software for classifying microarrays to nearest centroids , 2006, Bioinform..

[89]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[90]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[91]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[92]  R. Gafà,et al.  Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.

[93]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[94]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[95]  L. Chow,et al.  The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. , 2005, Cancer research.

[96]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[97]  Li Zhu,et al.  Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells1 , 2005, The Journal of Immunology.

[98]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[99]  D. English,et al.  Effect of physical activity and body size on survival after diagnosis with colorectal cancer , 2005, Gut.

[100]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[101]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[102]  A. Rowan,et al.  O6-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions , 2005, Gut.

[103]  M. Dell'aquila,et al.  Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF , 2005, Leukemia.

[104]  A. Rudensky,et al.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 , 2005, Nature Immunology.

[105]  Terry M. Therneau,et al.  Normalization of two-channel microarray experiments: a semiparametric approach , 2005, Bioinform..

[106]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[107]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[108]  Haiying Zhang,et al.  A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation , 2005, Oncogene.

[109]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[110]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Y. Okita,et al.  Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells , 2005, Cancer.

[114]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[115]  J. Issa CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[116]  N. Matsubara,et al.  Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Martin R. Johnson,et al.  Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography. , 2004, Analytical biochemistry.

[118]  Terry M. Therneau,et al.  Faster cyclic loess: normalizing RNA arrays via linear models , 2004, Bioinform..

[119]  S. Hankinson,et al.  Plasma vitamin D metabolites and risk of colorectal cancer in women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[120]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[121]  Aldi Kraja,et al.  Genome-wide discovery of loci influencing chemotherapy cytotoxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Bourhis,et al.  Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Martin Kupiec,et al.  A genome-wide screen for Saccharomyces cerevisiae deletion mutants that affect telomere length. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[124]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[125]  M. Stampfer,et al.  A prospective study of plasma C-peptide and colorectal cancer risk in men. , 2004, Journal of the National Cancer Institute.

[126]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[127]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[128]  E. Rimm,et al.  Height, predictors of C-peptide and cancer risk in men. , 2004, International journal of epidemiology.

[129]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[130]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[131]  M. Hyland,et al.  Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales , 1996, Quality of Life Research.

[132]  S. Groshen,et al.  Comparison of conditional quality of life terminology and visual analogue scale measurements , 1996, Quality of Life Research.

[133]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  J. Emerson,et al.  Colorectal cancer and solar radiation , 2004, Cancer Causes & Control.

[135]  Kensuke Matsumoto,et al.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[136]  M. Emi,et al.  Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer , 2003, Oncogene.

[137]  C. Ulrich,et al.  Cancer pharmacogenetics: polymorphisms, pathways and beyond , 2003, Nature Reviews Cancer.

[138]  N. Matsubara,et al.  Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[140]  H. Lieberman,et al.  Expression of mammalian paralogues of HRAD9 and Mrad9 checkpoint control genes in normal and cancerous testicular tissue. , 2003, Cancer research.

[141]  J. Meyerhardt,et al.  Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma , 2003, Cancer.

[142]  H. Lenz,et al.  Tailoring chemotherapy in advanced colorectal cancer. , 2003, Current opinion in pharmacology.

[143]  J. Cerhan,et al.  Cigarette smoking and colorectal cancer: long-term, subsite-specific risks in a cohort study of postmenopausal women. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[144]  Bruce A. Hay,et al.  The Drosophila MicroRNA Mir-14 Suppresses Cell Death and Is Required for Normal Fat Metabolism , 2003, Current Biology.

[145]  R. Russell,et al.  bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in Drosophila , 2003, Cell.

[146]  D. Banerjee,et al.  Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[147]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[148]  E. Giovannucci Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. , 2003, Journal of women's health.

[149]  E. Rimm,et al.  Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[150]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[151]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[152]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[153]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[154]  Richard M. Simon,et al.  A Paradigm for Class Prediction Using Gene Expression Profiles , 2003, J. Comput. Biol..

[155]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[156]  C. Cohen,et al.  Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis. , 2002, Cytometry.

[157]  J. Cerhan,et al.  High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. , 2002, Human pathology.

[158]  Ron H J Mathijssen,et al.  Modulation of irinotecan metabolism by ketoconazole. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  P. Korkolopoulou,et al.  The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. , 2002, Gynecologic oncology.

[160]  H. Stein,et al.  Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors , 2002, International journal of cancer.

[161]  A. Oliphant,et al.  BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. , 2002, BioTechniques.

[162]  C. Buskens,et al.  Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. , 2002, Gastroenterology.

[163]  U. Schumacher,et al.  CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  R. Cawthon Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[165]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[166]  Lee M Ellis,et al.  Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  Allen M. Gown,et al.  Improved Detection of Apoptotic Cells in Archival Paraffin Sections: Immunohistochemistry Using Antibodies to Cleaved Caspase 3 , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[168]  C. Allegra Thymidylate synthase levels: prognostic, predictive, or both? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  Makio Kobayashi,et al.  C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. , 2002, Anticancer research.

[170]  B. Weir,et al.  A systematic statistical linear modeling approach to oligonucleotide array experiments. , 2002, Mathematical biosciences.

[171]  K. Anderson,et al.  Associations between family history of colorectal cancer and genetic alterations in tumors , 2002, International journal of cancer.

[172]  Carol Reynolds,et al.  Centrosome amplification drives chromosomal instability in breast tumor development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[173]  J. Jobe,et al.  Cognitive research enhances accuracy of food frequency questionnaire reports: results of an experimental validation study. , 2002, Journal of the American Dietetic Association.

[174]  P. Quirke,et al.  Prediction of the response of colorectal cancer to systemic therapy. , 2002, The Lancet. Oncology.

[175]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[176]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[177]  S. Dudoit,et al.  STATISTICAL METHODS FOR IDENTIFYING DIFFERENTIALLY EXPRESSED GENES IN REPLICATED cDNA MICROARRAY EXPERIMENTS , 2002 .

[178]  S. Groshen,et al.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.

[179]  A. Krämer,et al.  Centrosome Aberrations and Cancer , 2001, Oncology Research and Treatment.

[180]  L. Mao,et al.  Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. , 2001, Cancer research.

[181]  D. Auclair,et al.  Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis. , 2001, Lung cancer.

[182]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[183]  E. Van Cutsem,et al.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  K. Mimori,et al.  Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[185]  D. Sargent,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[186]  S. Groshen,et al.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. , 2001, Anticancer research.

[187]  P. Laird,et al.  Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[188]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[189]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[190]  S. Lippman,et al.  Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[191]  E. Bajna,et al.  25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis , 2001, Steroids.

[192]  B. Leggett,et al.  Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. , 2001, Cancer research.

[193]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[194]  A. Freedman,et al.  Understanding the Interaction Between Environmental Exposures and Molecular Events in Colorectal Carcinogenesis , 2001, Cancer investigation.

[195]  N Rifai,et al.  Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. , 2001, The American journal of clinical nutrition.

[196]  J. Flanagan,et al.  25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. , 2001, Lancet.

[197]  Wei Zhang,et al.  Bax Induction Activates Apoptotic Cascade via Mitochondrial Cytochrome c Release and Bax Overexpression Enhances Apoptosis Induced by Chemotherapeutic Agents in DLD‐1 Colon Cancer Cells , 2000, Japanese journal of cancer research : Gann.

[198]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[199]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[200]  J. Deeds,et al.  Patterns of melastatin mRNA expression in melanocytic tumors. , 2000, Human pathology.

[201]  D J O'Kane,et al.  A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.

[202]  J. Peyrat,et al.  Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status , 2000, British Journal of Cancer.

[203]  G. Fontanini,et al.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[204]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  Yusuke Nakamura,et al.  Bcl‐XL Antisense Sensitizes Human Colon Cancer Cell Line to 5‐Fluorouracil , 2000, Japanese journal of cancer research : Gann.

[206]  M. Toyota,et al.  Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. , 2000, Cancer research.

[207]  D. Kerr,et al.  Adjuvant Therapy of Colorectal Cancer , 2000, Hospital practice.

[208]  Y Li,et al.  [Mitochondria and apoptosis]. , 2000, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[209]  W. Willett,et al.  A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[210]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[211]  D. Crivellari,et al.  MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[212]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[213]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  Li Zhu,et al.  Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.

[215]  W. Lingle,et al.  The role of the centrosome in the development of malignant tumors. , 2000, Current topics in developmental biology.

[216]  H. McLeod,et al.  Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? , 2000, European journal of cancer.

[217]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  K. Murphy,et al.  Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells , 2000, Cell Death and Differentiation.

[219]  A. Wyllie,et al.  Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability , 1999, Oncogene.

[220]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[221]  G. Peters,et al.  Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. , 1999, European journal of cancer.

[222]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  K. Sheahan,et al.  The relationship between cyclooxygenase-2 expression and colorectal cancer. , 1999, JAMA.

[224]  D. Schaid,et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.

[225]  F. Sinicrope,et al.  Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. , 1999, Gastroenterology.

[226]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[227]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[228]  T. Rummans,et al.  Quality of life in hospice patients. A pilot study. , 1999, Psychosomatics.

[229]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[230]  F. Sinicrope,et al.  Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[231]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[232]  J. Potter,et al.  Colorectal cancer: molecules and populations. , 1999, Journal of the National Cancer Institute.

[233]  R. Miike,et al.  Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[234]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  N. Ahuja,et al.  Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.

[236]  E. Raymond,et al.  Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[237]  M. Loda,et al.  HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. , 1999, Cancer research.

[238]  K. Hioki,et al.  Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. , 1999, Oncology reports.

[239]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[240]  B. Leggett,et al.  Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability , 1999, Oncogene.

[241]  P. Vreken,et al.  Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.

[242]  P. V. van Diest,et al.  Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. , 1998, Journal of clinical pathology.

[243]  D. Schaid,et al.  Reduced COX-2 protein in colorectal cancer with defective mismatch repair. , 1998, Cancer research.

[244]  H. McLeod,et al.  Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine , 1998, Annals of Internal Medicine.

[245]  O. Kronborg,et al.  Cytogenetic analysis of colorectal adenomas: karyotypic comparisons of synchronous tumors. , 1998, Cancer genetics and cytogenetics.

[246]  C. Erlichman,et al.  Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity , 1998, Cancer Chemotherapy and Pharmacology.

[247]  B. Trock,et al.  Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. , 1998, Chemico-biological interactions.

[248]  P. Rougier,et al.  Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. , 1998, Seminars in oncology.

[249]  J. Ingle,et al.  Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[250]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[251]  S. Guichard,et al.  Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. , 1998, Biochemical pharmacology.

[252]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  R. Labianca,et al.  Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[254]  C. Compton,et al.  Updated protocol for the examination of specimens removed from patients with colorectal carcinoma. A basis for checklists. , 1997, Archives of pathology & laboratory medicine.

[255]  F. Marshall,et al.  The national cancer data base , 1997, Cancer.

[256]  E. Raymond,et al.  Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers , 1997, Anti-cancer drugs.

[257]  J. Costello,et al.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene , 1997, Molecular and cellular biology.

[258]  T. Brent,et al.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. , 1997, Cancer research.

[259]  R. Goldberg,et al.  Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[260]  J. Lamb,et al.  Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c‐myc and bcl‐2 protein products , 1997, The Journal of pathology.

[261]  R. Poczatek,et al.  Prognostic significance of Bcl‐2 expression and p53 nuclear accumulation in colorectal adenocarcinoma , 1997, International journal of cancer.

[262]  D. Fairclough Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. , 1997, Statistics in medicine.

[263]  J. Robert,et al.  Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[264]  R. Gascoyne,et al.  Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. , 1997, Cancer research.

[265]  B. Hollis,et al.  Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. , 1997, Methods in enzymology.

[266]  M. Relling,et al.  Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. , 1997, Blood.

[267]  V. Bohr,et al.  Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. , 1996, Carcinogenesis.

[268]  R. Sandler Epidemiology and risk factors for colorectal cancer. , 1996, Gastroenterology clinics of North America.

[269]  N. Kemeny,et al.  Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  W. Willett,et al.  Calcium, vitamin D, and the occurrence of colorectal cancer among women. , 1996, Journal of the National Cancer Institute.

[271]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[272]  A. Piga,et al.  Assessing quality of life in patients with cancer: a comparison of a visual-analogue and a categorical model. , 1996, American journal of clinical oncology.

[273]  E. Rimm,et al.  Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. , 1996, American journal of epidemiology.

[274]  Thomas Ried,et al.  Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors , 1996, Genes, chromosomes & cancer.

[275]  A. V. Huis In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells , 1996 .

[276]  John Calvin Reed,et al.  BCL‐2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy , 1996, Journal of cellular biochemistry.

[277]  D. Osoba,et al.  Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. , 1996, Cancer treatment reviews.

[278]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[279]  T R Fleming,et al.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[280]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[281]  M. Tötsch,et al.  Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. , 1995, British Journal of Cancer.

[282]  T. Ley,et al.  Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[283]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[284]  C. Takimoto Enigma of fluorouracil and levamisole. , 1995, Journal of the National Cancer Institute.

[285]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[286]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[287]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[288]  F. Lévi,et al.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.

[289]  F. Révillion,et al.  1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. , 1994, Cancer letters.

[290]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[291]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[292]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[293]  R. vander Zwaag,et al.  From Dukes through Jass: pathological prognostic indicators in rectal cancer. , 1994, Human pathology.

[294]  A. Wyllie,et al.  Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. , 1994, The American journal of pathology.

[295]  O. Dent,et al.  Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients , 1994, Cancer.

[296]  Timothy J. Ley,et al.  Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells , 1994, Cell.

[297]  L. Harris,et al.  In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription. , 1994, Biochimica et biophysica acta.

[298]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[299]  L. Aaltonen,et al.  Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. , 1993, Cancer research.

[300]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[301]  G. Weiss,et al.  Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[302]  H. Rockette,et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[303]  J. Baselga,et al.  Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.

[304]  E. Rimm,et al.  Folate, methionine, and alcohol intake and risk of colorectal adenoma. , 1993, Journal of the National Cancer Institute.

[305]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[306]  D. Feldman,et al.  Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. , 1993, Endocrinology.

[307]  K. Ang,et al.  Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. , 1993, International journal of radiation biology.

[308]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[309]  P. Potter,et al.  Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. , 1991, Nucleic acids research.

[310]  H. Wieand,et al.  DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma , 1991, Cancer.

[311]  G. Blijham Chemotherapy of colorectal cancer. , 1991, Anti-cancer drugs.

[312]  S. Saez,et al.  Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. , 1991, Cancer Research.

[313]  A. Pegg,et al.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.

[314]  N. Lowe,et al.  A critical review of visual analogue scales in the measurement of clinical phenomena. , 1990, Research in nursing & health.

[315]  R. Mayer Does adjuvant therapy work in colon cancer? , 1990, The New England journal of medicine.

[316]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.

[317]  T. Fleming,et al.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[318]  N. Wolmark,et al.  Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). , 1989, Cancer.

[319]  H. Rockette,et al.  Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. , 1988, Journal of the National Cancer Institute.

[320]  A. Recht,et al.  Potentially curative surgery of colon cancer: patterns of failure and survival. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[321]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[322]  L. Melton,et al.  Predictors of survival after curative resection of carcinoma of the colon and rectum , 1987, Cancer.

[323]  J. Cuzick,et al.  The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases , 1986, Histopathology.

[324]  G. Littman,et al.  Reassessment of verbal and visual analog ratings in analgesic studies , 1985, Clinical pharmacology and therapeutics.

[325]  C. Willett,et al.  Obstructive and perforative colonic carcinoma: patterns of failure. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[326]  A. Wyllie The biology of cell death in tumours. , 1985, Anticancer research.

[327]  C. Willett,et al.  Failure Patterns Following Curative Resection of Colonic Carcinoma , 1984, Annals of surgery.

[328]  Van Blerk,et al.  Lymphoid infiltration and prognosis in colorectal carcinoma , 1984, British Journal of Cancer.

[329]  L Lasagna,et al.  Studies with different types of visual analog scales for measurement of pain , 1983, Clinical pharmacology and therapeutics.

[330]  S. Stewart-Brown,et al.  Histopathology reporting in large bowel cancer. , 1981, Journal of clinical pathology.

[331]  C. Moertel,et al.  Correlation of histopathologic characteristics of primary tumor and uninvolved regional lymph nodes in Dukes' class C colonic carcinoma with prognosis. , 1980, Mayo Clinic proceedings.

[332]  C. Garland,et al.  Do sunlight and vitamin D reduce the likelihood of colon cancer? , 1980, International journal of epidemiology.

[333]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[334]  H. Leveen,et al.  Adjuvant chemotherapy in the surgical treatment of large bowel cancer , 1976, Cancer.

[335]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[336]  J A Gottlieb,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972, Cancer chemotherapy reports.

[337]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[338]  U. Pastorino,et al.  Oxaliplatin Toxicity Masquerading As Recurrent Colon Cancer , 2022 .